Minesh P. Mehta, MD

0
Deputy Director and Chief of Radiation Oncology
Baptist Health South Florida and Miami Cancer Institute

Minesh P. Mehta, M.D., FASTRO, is the medical director at Maryland Proton Treatment Center at the University of Maryland. Board-certified in Radiation Oncology, Dr. Mehta specializes in the management of patients with benign and malignant tumors, vascular malformations, and other brain conditions such as trigeminal neuralgia, as well as in the area of thoracic tumors. He maintains an active interest in radiation-drug interactions, amelioration of radiation toxicities, incorporation of advanced radiation and imaging technologies, and is keenly interested in expanding the frontiers of personalized care in radiotherapy.

Dr. Mehta received his medical degree with highest honors from the University of Zambia, School of Medicine, in Lusaka, Zambia, where he received numerous awards through the course of his medical education. His radiation oncology training was completed at the University of Wisconsin Hospital in Madison in 1988.

Following his training, Dr. Mehta was appointed assistant professor of Human Oncology at the University of Wisconsin and joined the staff of the University of Wisconsin Hospital and Clinics, and served as a consultant at 10 area hospitals. In 1997 he was appointed as the Chairman of the Department of Human Oncology at the University of Wisconsin, and was promoted to Professor with Tenure. He was also appointed as the Chair of the Brain Tumor Committee of the Radiation Therapy Oncology Group. During this timeframe, he led the Imaging and Radiation Sciences Program of the University of Wisconsin Comprehensive Cancer Center, was the PI for a Program Project Grant and led the University of Wisconsin as the PI for the Brain Tumor Consortium Grant. He developed robust clinical research programs in thoracic and neuro-oncology, and also developed a state-wide network of Radiotherapy centers. In 2007, after 10 years as Department Chair, Dr. Mehta stepped down from administrative responsibilities while devoting time to national leadership efforts at the American Board of Radiology, the FDA Radiological Devices Panel, the American Society for Radiation Oncology, the American Society of Clinical Oncology, the International Stereotactic Radiosurgery Society, and the Society of Neuro-Oncology. In 2010, Dr. Mehta accepted the position of Professor of Radiation Oncology at Northwestern Memorial Hospital.

During his academic career, Dr. Mehta has lectured all over the world (over 500 presentations), and has authored more than 700 manuscripts, abstracts and book chapters. In 2010, as editor-in-chief, he published what is regarded as the definitive textbook in neuro-oncology. He has also provided leadership for over 100 clinical trials through clinical trials cooperative groups such as ECOG, CCG, COG, RTOG, NABTC, and ABTC, and has also led international, randomized multicenter clinical trials.

Dr. Mehta is a fellow of the American Society of Radiation Oncology. He is a member of several national and international medical societies, having provided a leadership role in several of these organizations

PATRICK Y. WEN, MD

0
Brigham And Women's Hospital


EDUCATIONAL TITLES
Professor, Neurology, Harvard Medical School Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION
Neuro-Oncology, Member

Research Abstract
My research is directed towards the deveiopment of new therapies for brain tumors and leptomeningeal metastases using gene therapy, inhibitors of angiogenesis, hormonal therapy and radionuclides. I am also interested in the neurologic complications in cancer patients.

Publications
Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. 2017; 19:625-635. PubMed

Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW. Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee. 2017. PubMed

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. 2017. PubMed

Wen PY, Jiang T, Schiff D. How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies. 2017; 19:459-460. PubMed

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Curr Opin Neurol 2017. PubMed

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol 2017. PubMed

van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. 2017. PubMed

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. 2017. PubMed

McFaline-Figueroa JR, Wen PY. The Viral Connection to Glioblastoma. Curr Infect Dis Rep 2017; 19:5. PubMed

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J. Neurooncol. 2017. PubMed

Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. 2017. PubMed

HUGUES DUFFAU

0

PhD Neurosciences, MD Neurosurgeon
8th August 1966, French, Married

Diploma

  • 1995: Medical Doctor, University Paris VI
  • 2000: PhD Neurosciences, University Paris VI
  • 2002: Habilitation, University Paris VI

Functions and Administrative Responsabilities

  • 2006: Professor of Neurosurgery
  • 2007: Head of the Department of Neurosurgery, Montpellier
  • 2010: Head of the Team "Brain plasticity, stem cells and glial tumors", INSERM U1051, Institute for Neurosciences of Montpellier
  • 2012: Member of the National Committee of University (CNU 49-02)
  • 2012: Member of the National Academy of Neurosurgery

Awards

  • 2001: Young Neurosurgeon Award, by the World Federation of Neurological Societies
  • 2009: Victory of Medicine (French National Award in Medicine 2009)
  • 2010: Victory of Medicine (French National Award in Medicine 2010)
  • 2010: Herbert Olivecrona Award (Karolinska Institute, Stockholm)
  • 2012: Grand Prix of Surgical Oncology, by the French National Academy of Medicine
  • 2013: Doctorate Honoris Causa (KU Leuven)
  • 2013: Doctorate Honoris Causa (University of Messina)

Member of Editorial Board

  • Brain and Language
  • Neurosurgery
  • Central European Neurosurgery
  • Acta Neurochirurgica
  • World Neurosurgery
  • Ad-hoc reviewer for 72 journals (510 reviews)

Societies

  • President of the Neurooncological Club of the French Neurosurgical Society
  • American Congress of Neurological Surgeons (CNS)
  • European Association for Neurooncology (EANO)
  • European Organization for Treatment of Cancer (EORTC)
  • French Association for Neurooncology (ANOCEF)

Expert

  • Member French Association Research for Cancer (ARC)
  • Expert, Netherlands Organisation for Health Research and Development (ZonMw) (2009 and 2013)
  • Expert, ANR Committee (2013)
  • Expert, European Research Council (2013)

Bibliography

  • h index = 57
  • g index = 95
  • 227 publications (10762 citations, Average per item 22.37)
  • 4 textbooks and 23 book chapters
  • 293 invited lectures (214 international and 79 national)
  • 219 oral communications or posters
  • 1 patent

ROGER STUPP

0
Text

MARTIN TAPHOORN

0
Text

Professor Michael Brada

0

Professor of Radiation Oncology, Department of Molecular and Clinical Cancer Medicine, University of Liverpool & Academic Unit of Radiation Oncology Clatterbridge Cancer Centre NHS Foundation Trust
BSc, MB ChB, FRCP, FRCR, DSc
mbrada@liverpool.ac.uk


Biography

Trained in general medicine, haematology and subsequently in radiotherapy and oncology. Previously Professor of Clinical Oncology at the Royal Marsden Hospital and the Institute of Cancer Research where he combined a busy clinical practice in brain tumours and lung cancer with a thriving academic neuro-oncology and lung cancer research. Currently Professor of Radiation Oncology at the University of Liverpool.

A world leading expert in neuro-oncology evaluating new treatments, including new drugs, biological therapy and new radiation therapy techniques. Leading expert in novel treatments in lung cancer. Authored or co-authored more than 250 peer-reviewed articles, editorials, and book chapters in leading textbooks; invited lectures at many national and international conferences and meetings.

Served as the President of the European Association of Neuro-oncology (EANO), President of The European Society of Therapeutic Radiation Oncology (ESTRO). An honorary member of radiation oncology societies throughout the world and founding Fellow of European Academy of Cancer Sciences.


Clinical & Research interests

Developing and testing new approaches to therapy and care of patients with lung cancer with particular focus on imaging, novel radiotherapy technology and combination of radiation with targeted agents.

Teaching Involved primarily in postgraduate education at national and international level through teaching courses as both a teacher and course organiser.

ANDREAS VON DIEMLING

0

Department of Neuropathology
Institute for Pathology
University of Heidelberg
INF 220/221
69120 Heidelberg
Germany
Phone: +49-6221-562603
Fax: +49-6221-564566
Email: andreas.vondeimling@med.uni-heidelberg.de
Website: www.klinikum.uni-heidelberg.de/neuropathologie.370.0.html

Research Summary
The research focus is on human tumours of the CNS and PNS. Lines of investigation include the search for genes involved in the initiation or progression of these tumors, mechanisms of epigenetic regulation, mechanisms of apoptosis, novel functions of the NF1 gene and molecular analyses in preclinical and clinical studies.

Structure of the Group
Group Leader: Andreas von Deimling
Scientists: Christian Hartmann, Wolf Müller, David Reuss, Jörg Balss, David Capper, Andrey Korshunov
Technicians: Antje Habel, Ulrike Lass, Jochen Meier, Franziska Mößler, Jana Mucha, Kerstin Weber


M. R. SATYANARAYANA RAO

0

FNASc, FASc, FNA, FAMS, FTWAS
Civilian Honor: Padma Shri, Govt. of India, 2010
Professor
Chromatin Biology Laboratory
Molecular Biology and Genetics Unit (MBGU)
Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR)
Bangalore, India.

ACADEMICS
Postdoctoral Research - Baylor College of Medicine, Houston, Texas, USA, 1974-76
Ph.D. - Indian Institute of Science, Bangalore, India, 1973
M.Sc. - Bangalore University, 1968
B.Sc. - Bangalore University, 1966

PROFESSIONAL CAREER

UNIVERSITY/INSTITUTION

YEAR

POSITION

Baylor College of Medicine, USA

1974-75

Research Associate

Baylor College of Medicine, USA

1975 - 76

Instructor

Baylor College of Medicine, USA

1976 - 78

Assistant Professor

Indian Institute of Science, Bangalore

1978 - 82

Sr. Research Fellow, IISc

Indain Institute of Science, Bangalore

1982 - 87

Assistant Professor

Indian Institute of Science, Bangalore

1987 - 91

Associate Professor

Indian Institute of Science, Bangalore

1991 - 09

Professor, IISc

Indian Institute of Science, Bangalore

1990 - 93

Chairman, Centre for Genetic Engineering

Baylor College of Medicine, USA

1983

Visiting Assistant Professor

Baylor College of Medicine, USA

1986

Research Associate Professor

Harvard Medical School, USA

1988 - 90

Visiting Associate Professor

Harvard Medical School, USA

1993

Visiting Professor

Indian Institute of Science, Bangalore

1998 - 03

Chairman, Department of Biochemistry

Ludwig Institute for Cancer Research, University of California at San Diego, USA

1998

Visiting Scientist

Indian Institute of Science, Bangalore

2001 - 03

Astra Professor

Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore

2003 -2013

President

Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore

2013-till date

Honorary Professor

Prof. P.N. Tandon

0

Prof. P.N. Tandon (1965-1990) presently Emeritus Professor Neurosurgery
“The Departments of Neurology and Neurosurgery at the All India Institute of Medical Sciences were initiated in March 1965 with the appointment of Prof. Baldev Singh and myself as the first Professors. A neurology service in the Department of Medicine started by Dr. Jim Austin from the USA and later under care of Dr. Vimla Virmani was already in existence at that time. Significantly enough the Institute was, from its very inception, an important centre of neuroscience research. The first two Professors in Department of Physiology (Prof. B.K. Anand and Prof. A.S. Paintal) were undisputable leaders of neurophysiology in the country. Dr. Paintal had, however, already moved to Patel Chest Institute a year earlier, the remaining faculty members of the department were all pursuing neurophysiology research. Prof. Keswani, the Chief of Anatomy, was primarily interested in neuroanatomy. Prof. G. P. Talwar, at that stage, was enthusiastically involved in researches in neurochemistry This was of course before his shift to immunology. Acknowledging these strengths International Brain Research Organization (IBRO) had already held one of its earlier workshops in the Institute. Dr. Sriramachari, Deputy Director of Indian Council of Medical Research, though not on the faculty of the Institute freely provided his services for all neuropathological work till several years later when Dr. Subimal Roy took over the responsibility fully. While clinical neurology and neurosurgery departments existed at several centers in the country much earlier; even the oldest such centers at Vellore, Madras, Bombay and Calcutta, did not have such broad base of neuroscience as we were fortunate to have at the Institute. Given the overall milieu of rapid growth and development in the institute at that time, the clinical departments also expanded rapidly. It will be hard for the current staff and students of the Institute to visualize how close interaction existed among all these departments and units in the earlier years. This was in no small measure due to the all pervading influence of Prof. Baldev Singh real father figure for all of us.

The idea of establishing a "Brain Research Centre" at the Institute had already been envisaged by Prof. B.K. Anand even before the clinical departments came into existence. No doubt this was primarily thought of as a basic research centre. Thus on 1st December 1964, Dr. Anand vide his letter No. Phy/64/1235 requested the Director for initiating steps for developing a Brain Research Centre" with the existing ICMR Neurophysiology unit as its nucleus. Unfortunately no action was taken on his request.

In 1968, when the Institute was to formulate its development plans for the Fourth Five Year plan of the Government, Prof. Anand, Prof. Baldev Singh and I had several informal discussions to once again revive the proposal for a Brain Research Centre. It may be mentioned that, not surprisingly, this proposal was heavily loaded in favour of creating research laboratories including a couple for neurology and neurosurgery. While we were heavily constrained in our clinical work due to limited diagnostic and operative facilities at this time we went along with Prof. Anand in supporting this proposal hoping to strengthen the patient care services through the development plan for the Institute hospital which was to be commissioned

The Development Committee approved the proposal in principle, but owing to financial constraints no concrete steps were taken. The Institute Body ultimately agreed to create a few staff positions so that "Centre can make a start as early as the Financial Year 1970/71. In practical terms it amounted to absorbing some of the staff of the Indian Council of Medical Research Neurophysiology Unit and nothing more.

When we finally shifted to the new hospital the Neurosurgery Department had 22 beds allotted to it. We had one operation theatre, but no specialized neurosurgical operation table and no intensive care unit. The neuroradiology set up consisted of a skull table without automatic changer for angiography, no facilities for tomography nor a dedicated unit for myelography. Isotope encephalometry then a routine diagnostic investigation abroad was nonexistent. We had an EEG machine but no facilities for EMG or nerve conduction. Nonetheless we were facing increasing demands for patient care from all over the country and also our neighboring countries. Waiting lists for admission and surgery were a constant source of worry for us and frustration for the suffering patients. We had already started the M. Ch. course.

  • isnosecretary@gmail.com
  • Contact Us
  • Call us now! +91 - 22 - 2417 7153

Apicona

For your health

Toggle menu

Skip to content
  • Home
  • ABOUT ISNO
    • Constitution
    • GBM Minutes 2015
    • GBM Minutes 2016
  • Messages
    • President
    • Secretary
    • Imm. Past President
  • Committees
    • Executive Committee
    • Advisory Council
    • Past Committee
  • Events
    • Forthcoming Events
    • Past Events
  • ISNO ORATIONS
    • Ab Guha Oration
    • Presidential Oration
    • Subimal Roy Oration
  • Publications
    • International Journal of Neuro-Oncology
    • Important Journals
    • ISNO Position Statement on Treatment Guidance in Neuro-Oncology during Pandemics
    • Useful Links
  • Forum
  • Awards & Fellowships
    • Call for Application
    • Previous Awardees
  • Contact Us

Ab Guha Oration

Home  ⁄    Ab Guha Oration
0

Thomas Merchant

Kolkata , 2023

David Louis

Gurugram , 2022

0

Mark Gilbert

Vellore-Online , 2021

0

Eric Bouffet

Bhopal , 2019

0

Raymond Sawaya

New Delhi , 2018
0

Minesh Mehta

Benagluru, 2017
0

Patrick Wen

Hyderabad, 2016
0

Hugues Duffau

Kochi, 2015

0

Roger Stupp

Mumbai, 2013

0

Martin Taphoorn

Lucknow, 2014

0

Michael Brada

Bangalore, 2012

0

Andreas von Diemling

Kolkata, 2011

0

M R S Rao

Chennai, 2010

0

PN Tandon

New Delhi, 2009
About ISNO
NeuroOncological tumors represents a diverse group of benign and malignant tumors arising from the central or peripheral nervous system, which recognizes no geographical, racial, gender, social or age boundaries. Significant progress has been achieved in our understanding and managment of these tumors, however, patients with malignant brain, spinal and peripheral nerve tumors still have a guarded prognosis.

Read More

Quick Links

  • Home
  • President's Message
  • Secretary's Message
  • Committee
  • Publication
  • Awards & Fellowships
  • Useful Links

ABOUT ISNO

  • Constitution
  • Directory
  • GBM Minutes

Contact Us

  • Office: 1129, 11th floor, Homi Bhabha Block, Tata Memorial Hospital, Dr. Ernest Borges Marg, Parel, Mumbai - 400 012, INDIA
  • +91 - 22 - 2417 7153

  • +91 - 22 - 2414 6937

  • isnosecretary@gmail.com

Copyright © 2016 Indian Society of Neuro-Oncology (ISNO) | All rights reserved.
Designed By Creative minds